Registration

DLA PIPER LLP (US) for BIOGEN, INC.

Firm
Client
Income
—
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.

LobbyistCovered position, as disclosed
RICHARD BURR New U.S. Senator
KARINA LYNCH New —
MARGARET MARTIN New Senior FDA Policy Advisor, Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard Burr
MICHAEL SORENSEN New Scheduler and other positions, Sen. Richard Burr; Intern, Rep. John Boehner; Intern, Rep. Mike Kelly

Health Issues HCR

Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.

LobbyistCovered position, as disclosed
RICHARD BURR New U.S. Senator
KARINA LYNCH New —
MARGARET MARTIN New Senior FDA Policy Advisor, Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard Burr
MICHAEL SORENSEN New Scheduler and other positions, Sen. Richard Burr; Intern, Rep. John Boehner; Intern, Rep. Mike Kelly

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.